메틸페니데이트

용도

• Treatment of narcolepsy/cataplexy
• Treatment of narcolepsy/cataplexy (to supplement imipramine)
• Diagnosis and treatment of hyperkinesis
• Hyperkinesis-hyperactivity

투여 방법

가능한 부작용

• Tachycardia (increased heart rate)
• Tachypnea (increased respiratory rate)
• Anorexia
• Tremors
• Hyperthermia (particularly exercise-induced)

주의사항 및 금기

• Seizure disorders
• Cardiac disease or hypertension
• Aggressive animals
• Use with extreme caution in dogs with pre-existing seizure disorders, cardiac disease, hypertension, or those exhibiting aggressive behavior. Methylphenidate is a Class-II controlled substance with a high potential for human abuse; prescribe and dispense with strict adherence to controlled substance regulations.

약물 상호작용

• Anticonvulsants (phenobarbital, primidone, phenytoin): Methylphenidate may increase serum levels of these anticonvulsants
• Clonidine: Rare cases of cardiovascular effects (including death) reported in humans; mechanism unknown
• Hypotensive drugs: Methylphenidate may reduce the efficacy of hypotensive effects
• MAO Inhibitors (amitraz, selegiline): Concurrent use could lead to a severe hypertensive crisis
• SSRI Antidepressants (fluoxetine, sertraline): Methylphenidate may inhibit SSRI metabolism and increase their serum levels
• Tricyclic Antidepressants (amitriptyline, clomipramine): Methylphenidate may inhibit TCA metabolism and increase their serum levels
• Warfarin: Methylphenidate may inhibit warfarin metabolism and increase INR

자주 묻는 질문